Why Did Moderna Stock Crash 17% Despite Positive Cancer Vaccine Results?
Photo: Coinpedia
Moderna stock (NASDAQ: MRNA) plunged 17.57% to $202.63 on Thursday, October 22, after detailed Phase 3 cancer vaccine results triggered a sharp sell-the-news reaction. The personalized cancer vaccine, developed with Merck, reduced the risk of melanoma recurrence or death by 42% when combined with Keytruda. Moderna stock suffered a sharp panic drop on Thursday, falling 17.57% to close at $202.63 despite promising results from its experimental personalized cancer vaccine. The sell-off followed the early publication of Phase 3 trial data for intismeran autogene, developed in partnership with Merck.
Also reported by The Crypto Basic.
Source: Coinpedia
